Skip to main content
Journal cover image

Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D.

Publication ,  Journal Article
Church, JD; Jones, D; Flys, T; Hoover, D; Marlowe, N; Chen, S; Shi, C; Eshleman, JR; Guay, LA; Jackson, JB; Kumwenda, N; Taha, TE; Eshleman, SH
Published in: J Mol Diagn
September 2006

The US Food and Drug Administration-cleared ViroSeq HIV-1 Genotyping System (ViroSeq) and other population sequencing-based human immunodeficiency virus type 1 (HIV-1) genotyping methods detect antiretroviral drug resistance mutations present in the major viral population of a test sample. These assays also detect some mutations in viral variants that are present as mixtures. We compared detection of the K103N nevirapine resistance mutation using ViroSeq and a sensitive, quantitative point mutation assay, LigAmp. The LigAmp assay measured the percentage of K103N-containing variants in the viral population (percentage of K103N). We analyzed 305 samples with HIV-1 subtypes A, C, and D collected from African women after nevirapine administration. ViroSeq detected K103N in 100% of samples with >20% K103N, 77.8% of samples with 10 to 20% K103N, 71.4% of samples with 5 to 10% K103N, and 16.9% of samples with 1 to 5% K103N. The sensitivity of ViroSeq for detection of K103N was similar for subtypes A, C, and D. These data indicate that the ViroSeq system reliably detects the K103N mutation at levels above 20% and frequently detects the mutation at lower levels. Further studies are needed to compare the sensitivity of different assays for detection of HIV-1 drug resistance mutations and to determine the clinical relevance of HIV-1 minority variants.

Duke Scholars

Published In

J Mol Diagn

DOI

ISSN

1525-1578

Publication Date

September 2006

Volume

8

Issue

4

Start / End Page

430 / 432

Location

United States

Related Subject Headings

  • Sequence Analysis, DNA
  • Sensitivity and Specificity
  • Reagent Kits, Diagnostic
  • Polymerase Chain Reaction
  • Point Mutation
  • Pathology
  • Nevirapine
  • Mutation
  • Humans
  • HIV-1
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Church, J. D., Jones, D., Flys, T., Hoover, D., Marlowe, N., Chen, S., … Eshleman, S. H. (2006). Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn, 8(4), 430–432. https://doi.org/10.2353/jmoldx.2006.050148
Church, Jessica D., Dana Jones, Tamara Flys, Donald Hoover, Natalia Marlowe, Shu Chen, Chanjuan Shi, et al. “Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D.J Mol Diagn 8, no. 4 (September 2006): 430–32. https://doi.org/10.2353/jmoldx.2006.050148.
Church JD, Jones D, Flys T, Hoover D, Marlowe N, Chen S, et al. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn. 2006 Sep;8(4):430–2.
Church, Jessica D., et al. “Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D.J Mol Diagn, vol. 8, no. 4, Sept. 2006, pp. 430–32. Pubmed, doi:10.2353/jmoldx.2006.050148.
Church JD, Jones D, Flys T, Hoover D, Marlowe N, Chen S, Shi C, Eshleman JR, Guay LA, Jackson JB, Kumwenda N, Taha TE, Eshleman SH. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn. 2006 Sep;8(4):430–432.
Journal cover image

Published In

J Mol Diagn

DOI

ISSN

1525-1578

Publication Date

September 2006

Volume

8

Issue

4

Start / End Page

430 / 432

Location

United States

Related Subject Headings

  • Sequence Analysis, DNA
  • Sensitivity and Specificity
  • Reagent Kits, Diagnostic
  • Polymerase Chain Reaction
  • Point Mutation
  • Pathology
  • Nevirapine
  • Mutation
  • Humans
  • HIV-1